Denali Therapeutics (DNLI) Retained Earnings (2017 - 2026)
Denali Therapeutics (DNLI) reported Retained Earnings of -$682000.0 for Q1 2026, down 133.48% year-over-year from $2.0 million in Q1 2025, and up 99.97% on a QoQ basis from -$2.1 billion in Q4 2025.
Denali Therapeutics (DNLI) has 10 years of Retained Earnings data on file, last reported at -$682000.0 in Q1 2026.
- Quarterly Retained Earnings fell 133.48% year-over-year to -$682000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$682000.0 (down 133.48% YoY) and the FY2025 annual result came in at -$2.1 billion, down 33.3% from the prior year.
- Retained Earnings improved to -$682000.0 in Q1 2026 per DNLI's latest filing, from -$2.1 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $2.0 million in Q1 2025 and bottomed at -$2.1 billion in Q4 2025.
- The 5-year median for Retained Earnings is -$769.0 million (2022), against an average of -$674.4 million.
- The widest annual swing landed in 2022, when Retained Earnings slumped 208870.11%; it then surged 257.18% in 2025.
- Tracing DNLI's Retained Earnings over 5 years: stood at -$6.9 million in 2022, then sank by 16109.86% to -$1.1 billion in 2023, then slumped by 37.88% to -$1.5 billion in 2024, then slumped by 33.3% to -$2.1 billion in 2025, then surged by 99.97% to -$682000.0 in 2026.
- Per Business Quant, the three latest DNLI Retained Earnings figures stand at -$682000.0 (Q1 2026), -$2.1 billion (Q4 2025), and $1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | -682,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -682,000.00 |
| Dec 31, 2025 | -2.05 Bn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 939,000.00 |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | -1.54 Bn |
| Sep 30, 2024 | -1.42 Bn |
| Jun 30, 2024 | -2.66 Mn |
| Mar 31, 2024 | -1.30 Mn |
| Dec 31, 2023 | -1.12 Bn |
| Sep 30, 2023 | -996.74 Mn |
| Jun 30, 2023 | -897.39 Mn |
| Mar 31, 2023 | -1.08 Bn |
| Dec 31, 2022 | -6.89 Mn |
| Sep 30, 2022 | -872.31 Mn |
| Jun 30, 2022 | -769.01 Mn |
| Mar 31, 2022 | -710.22 Mn |
| Dec 31, 2021 | -2.50 Mn |
| Sep 30, 2021 | -521,000.00 |
| Jun 30, 2021 | -368,000.00 |
| Mar 31, 2021 | -424.46 Mn |
| Dec 31, 2020 | -245,000.00 |
| Sep 30, 2020 | 11,000.00 |
| Jun 30, 2020 | 551,000.00 |
| Mar 31, 2020 | 835,000.00 |
| Dec 31, 2019 | -425.55 Mn |
| Sep 30, 2019 | -371.53 Mn |
| Jun 30, 2019 | -325.27 Mn |
| Mar 31, 2019 | 332,000.00 |
| Dec 31, 2018 | -649,000.00 |
| Sep 30, 2018 | -1.42 Mn |
| Jun 30, 2018 | -270.10 Mn |
| Mar 31, 2018 | -1.29 Mn |
| Dec 31, 2017 | -191.70 Mn |